Novel Biomarkers Predict CV Events in Type 2 Diabetes
By LabMedica International staff writers Posted on 20 Sep 2018 |
Image: High magnification micrograph of senile cardiac amyloidosis from an autopsy specimen (Photo courtesy of Nephron).
Cardiovascular disease generally refers to conditions that involve narrowed or blocked blood vessels that can lead to a heart attack, chest pain (angina) or stroke. Cardiovascular disease (CVD) risk prediction represents an increasing clinical challenge in the treatment of diabetes.
A panel of vascular imaging, functional assessments, and biomarkers reflecting different disease mechanisms has been used to identify clinically useful markers of risk for cardiovascular (CV) events in subjects with type 2 diabetes (T2D) with or without manifest CVD.
A team of scientists led by those at the University of Exeter (Exeter, UK) recruited 936 subjects with T2D at four European centers. Carotid intima-media thickness and plaque area, ankle-brachial pressure index, arterial stiffness, endothelial function, and circulating biomarkers were analyzed at baseline, and CV events were monitored during a three-year follow-up period.
The investigators reported that the CV event rate in 440 subjects with T2D was statistically higher in those with than in those 496 without manifest CVD at baseline (5.53 versus 2.15/100 life-years). New CV events in subjects with T2D with manifest CVD were associated with higher baseline levels of inflammatory biomarkers such as interleukin 6, chemokine ligand 3, pentraxin 3, and high sensitivity C-reactive protein (hs-CRP) and endothelial mitogens represented by, hepatocyte growth factor and vascular endothelial growth factor A. However, CV events in subjects with T2D without manifest CVD were associated with more severe baseline atherosclerosis (median carotid plaque area 34.5 mm2 versus 19.5 mm2. Conventional risk factors, as well as measurements of arterial stiffness and endothelial reactivity, were not associated with CV events.
The authors concluded that their observations demonstrate that markers of inflammation and endothelial stress reflect CV risk in subjects with T2D with manifest CVD, whereas the risk for CV events in subjects with T2D without manifest CVD is primarily related to the severity of atherosclerosis. The study was published on July 6, 2018, in the journal Diabetes Care.
Related Links:
University of Exeter
A panel of vascular imaging, functional assessments, and biomarkers reflecting different disease mechanisms has been used to identify clinically useful markers of risk for cardiovascular (CV) events in subjects with type 2 diabetes (T2D) with or without manifest CVD.
A team of scientists led by those at the University of Exeter (Exeter, UK) recruited 936 subjects with T2D at four European centers. Carotid intima-media thickness and plaque area, ankle-brachial pressure index, arterial stiffness, endothelial function, and circulating biomarkers were analyzed at baseline, and CV events were monitored during a three-year follow-up period.
The investigators reported that the CV event rate in 440 subjects with T2D was statistically higher in those with than in those 496 without manifest CVD at baseline (5.53 versus 2.15/100 life-years). New CV events in subjects with T2D with manifest CVD were associated with higher baseline levels of inflammatory biomarkers such as interleukin 6, chemokine ligand 3, pentraxin 3, and high sensitivity C-reactive protein (hs-CRP) and endothelial mitogens represented by, hepatocyte growth factor and vascular endothelial growth factor A. However, CV events in subjects with T2D without manifest CVD were associated with more severe baseline atherosclerosis (median carotid plaque area 34.5 mm2 versus 19.5 mm2. Conventional risk factors, as well as measurements of arterial stiffness and endothelial reactivity, were not associated with CV events.
The authors concluded that their observations demonstrate that markers of inflammation and endothelial stress reflect CV risk in subjects with T2D with manifest CVD, whereas the risk for CV events in subjects with T2D without manifest CVD is primarily related to the severity of atherosclerosis. The study was published on July 6, 2018, in the journal Diabetes Care.
Related Links:
University of Exeter
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms